Which of the following statements about chemoprevention trials is true?

Which of the following statements about chemoprevention trials is true?

• A. Only women can participate in such trials
• B. They are exclusively for late-stage cancer patients
• C. They may include individuals with significant family history of cancer
• D. They focus only on chemotherapy treatments

Answer: (C)

The statement that chemoprevention trials may include individuals with significant family history of cancer is correct. Chemoprevention refers to the use of natural or synthetic substances to reduce the risk of cancer, particularly in populations at high risk. Individuals with a significant family history of cancer are often considered high-risk for developing certain cancers, such as breast or ovarian cancer. Therefore, they are eligible to participate in these trials to assess the effectiveness of preventive agents aimed at reducing cancer incidence in their specific demographic. In the context of other options, trials are not limited to women, as both men and women can be involved, especially with regard to cancers that affect both genders. Furthermore, chemoprevention trials are not restricted to late-stage cancer patients; they often target individuals who are at increased risk for developing cancer rather than those who already have it. Finally, these trials do not focus solely on chemotherapy treatments; instead, they explore a range of preventive interventions, which may include hormonal agents, vitamins, or other medications.

The statement that chemoprevention trials may include individuals with significant family history of cancer is correct. Chemoprevention refers to the use of natural or synthetic substances to reduce the risk of cancer, particularly in populations at high risk. Individuals with a significant family history of cancer are often considered high-risk for developing certain cancers, such as breast or ovarian cancer. Therefore, they are eligible to participate in these trials to assess the effectiveness of preventive agents aimed at reducing cancer incidence in their specific demographic.

In the context of other options, trials are not limited to women, as both men and women can be involved, especially with regard to cancers that affect both genders. Furthermore, chemoprevention trials are not restricted to late-stage cancer patients; they often target individuals who are at increased risk for developing cancer rather than those who already have it. Finally, these trials do not focus solely on chemotherapy treatments; instead, they explore a range of preventive interventions, which may include hormonal agents, vitamins, or other medications.